Hostname: page-component-76fb5796d-dfsvx Total loading time: 0 Render date: 2024-04-26T23:25:23.742Z Has data issue: false hasContentIssue false
  • English
  • Français

Shift from first generation antipsychotics to olanzapine may improve health-related quality of life of stable but residually symptomatic schizophrenic outpatients: A prospective, randomized study

Published online by Cambridge University Press:  01 October 2008

Grigori Joffe ,
Harri Sintonen  and
Björn Appelberg
Grigori Joffe
Affiliation:
Helsinki University Central Hospital
Harri Sintonen
Affiliation:
University of Helsinki
Björn Appelberg
Affiliation:
Helsinki University and Helsinki University Central Hospital
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The aim of this study was to elucidate, whether shift from first generation antipsychotics (FGA) to olanzapine can affect health-related quality of life (HRQoL) of residually symptomatic schizophrenic outpatients.

Methods: Patients were randomized to either olanzapine or to continuation on their FGA. The 15D-measured HRQoL at baseline and end-point (after 12 weeks) was compared.

Results: Patients (n = 21) randomized to olanzapine achieved better HRQoL than those (n = 21) who continued on their FGA. This difference on the 15D (0.048 on a 0–1 scale; p = .037) was clinically important and comparable to that resulting from common surgical interventions, for example, hip or knee replacement.

Conclusions: HRQoL of stable outpatients with residual symptoms or adverse effects may improve substantially after shift from FGAs to olanzapine.

Keywords

SchizophreniaOlanzapineAtypical antipsychoticsConventional antipsychotics15D
Type
GENERAL ESSAYS
Information
International Journal of Technology Assessment in Health Care , Volume 24 , Issue 4 , October 2008 , pp. 399 - 402
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Appelberg, B, Tuisku, K, Joffe, G. Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomized study with olanzapine. Eur Psychiatry. 2004;19:516–518.CrossRefGoogle ScholarPubMed
2. Kattainen, E, Meriläinen, P, Sintonen, H. Sense of coherence and health-related quality of life among patients undergoing coronary artery bypass grafting or angioplasty. Eur J Cardiovasc Nurs. 2006;5:21–30.CrossRefGoogle ScholarPubMed
3. Revicki, DA, Genduso, LA, Hamilton, SH, Ganoczy, D, Beasley, CM. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. 1999;6:417–426.CrossRefGoogle Scholar
4. Räsänen, P, Öhman, J, Sintonen, H et al. . Cost-utility analysis of routine neurosurgical spinal surgery. J Neurosurg Spine. 2006;5:204–209.CrossRefGoogle ScholarPubMed
5. Räsänen, P, Krootila, K, Sintonen, H et al. . Cost-utility of routine cataract surgery. Health Qual Life Outcomes. 2006;4:74.CrossRefGoogle ScholarPubMed
6. Räsänen, P, Paavolainen, P, Sintonen, H et al. . Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs. Acta Orthopaed. 2007;78:108–115.CrossRefGoogle ScholarPubMed
7. Sintonen, H. Outcome measurement in acid-related diseases. Pharmacoeconomics. 1994;5 (suppl 3):17–26.CrossRefGoogle Scholar
8. Sintonen, H. The 15D instrument of health-related quality of life: Properties and applications. Ann Med. 2001;33:328–336.CrossRefGoogle ScholarPubMed
9. Strakowski, SM, Johnson, JL, Delbello, MP et al. . Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schisophr Res. 2005;78:161–169.CrossRefGoogle ScholarPubMed
10. Voruganti, L, Cortese, L, Oyewumi, L et al. . Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side effect profile and impact on quality of life. Schizophr Res. 2000;43:135–145.CrossRefGoogle ScholarPubMed